SCYNEXIS, Inc. To Present At Cantor Fitzgerald’s 2nd Annual Healthcare Conference
JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (SCYX) today announced that the Company will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference at Le Parker Meridien New York on Tuesday, July 12, 2016 at 9:00 a.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS is developing its lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.
- Health Care Industry
Media Relations
Heather Savelle
MacDougall Biomedical Communications
Tel: 781.235.3060
hsavelle@macbiocom.com
Investor Relations
Susan Kim
Argot Partners
Tel: 212.203.4433
susan@argotpartners.com